

Cover Story
A health services researcher at Memorial Sloan-Kettering Cancer Center has proposed a method for assessing whether cancer drugs are rationally priced.
By Nick Crispino and Matthew Bin Han Ong
In Brief
Drugs & Targets
Trending Stories
- Anthony G. Letai to be named NCI director
The Dana-Farber and Harvard physician-scientist is an inspired choice, colleagues say - With Anthony Letai’s appointment, NCI is now under new leadership—just in time for a shutdown
- Trump’s FDA invents an unusual regulatory pathway to approve leucovorin for autism
Experts call the move “extremely premature” - Bhattacharya: New grant review criterion is “not political”
- Population-based cancer surveillance is a national treasure at risk
- Anthony Letai sworn in as 18th NCI director